Report Detail
Global RNA Interference (RNAi) Drug Delivery Market Insights and Forecast to 2026
- RnM4087762 |
- 02 July, 2020 |
- Global |
- 110 Pages |
- QYResearch |
- Medical Devices & Consumables
RNA Interference (RNAi) Drug Delivery market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global RNA Interference (RNAi) Drug Delivery market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the RNA Interference (RNAi) Drug Delivery market is segmented into
Nanoparticle Drug Delivery Technology
Pulmonary Drug Delivery Technology
Nucleic Acid Drug Delivery Technology
Aptamer Drug Delivery Technology
Segment by Application, the RNA Interference (RNAi) Drug Delivery market is segmented into
Infectious Diseases
Cardiology
Oncology
Neurology
Ophthalmology
Metabolic Disorders
Regional and Country-level Analysis
The RNA Interference (RNAi) Drug Delivery market is analysed and market size information is provided by regions (countries).
The key regions covered in the RNA Interference (RNAi) Drug Delivery market report are North America, Europe, China and Japan. It also covers key regions (countries), viz, the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of production capacity, price and revenue for the period 2015-2026.
Competitive Landscape and RNA Interference (RNAi) Drug Delivery Market Share Analysis
RNA Interference (RNAi) Drug Delivery market competitive landscape provides details and data information by manufacturers. The report offers comprehensive analysis and accurate statistics on production capacity, price, revenue of RNA Interference (RNAi) Drug Delivery by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on production, revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue, and the production capacity, price, revenue generated in RNA Interference (RNAi) Drug Delivery business, the date to enter into the RNA Interference (RNAi) Drug Delivery market, RNA Interference (RNAi) Drug Delivery product introduction, recent developments, etc.
The major vendors covered:
Metabolic disorders
Alnylam Pharmaceuticals Inc
Merck & Co. Inc
Access Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Calondo Pharmaceuticals Inc
Marina Biotech Inc
RXi Pharmaceuticals Corp
Quark Pharmaceuticals Inc
Silence Therapeutics plc
Tacere Therapeutics Inc
PhaseRx Inc
Sirnaomics Inc
Traversa Therapeutics Inc
1 Study Coverage
- 1.1 RNA Interference (RNAi) Drug Delivery Product Introduction
- 1.2 Key Market Segments in This Study
- 1.3 Key Manufacturers Covered: Ranking of Global Top RNA Interference (RNAi) Drug Delivery Manufacturers by Revenue in 2019
- 1.4 Market by Type
- 1.4.1 Global RNA Interference (RNAi) Drug Delivery Market Size Growth Rate by Type
- 1.4.2 Nanoparticle Drug Delivery Technology
- 1.4.3 Pulmonary Drug Delivery Technology
- 1.4.4 Nucleic Acid Drug Delivery Technology
- 1.4.5 Aptamer Drug Delivery Technology
- 1.5 Market by Application
- 1.5.1 Global RNA Interference (RNAi) Drug Delivery Market Size Growth Rate by Application
- 1.5.2 Infectious Diseases
- 1.5.3 Cardiology
- 1.5.4 Oncology
- 1.5.5 Neurology
- 1.5.6 Ophthalmology
- 1.5.7 Metabolic Disorders
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global RNA Interference (RNAi) Drug Delivery Market Size, Estimates and Forecasts
- 2.1.1 Global RNA Interference (RNAi) Drug Delivery Revenue Estimates and Forecasts 2015-2026
- 2.1.2 Global RNA Interference (RNAi) Drug Delivery Production Capacity Estimates and Forecasts 2015-2026
- 2.1.3 Global RNA Interference (RNAi) Drug Delivery Production Estimates and Forecasts 2015-2026
- 2.2 Global RNA Interference (RNAi) Drug Delivery, Market Size by Producing Regions: 2015 VS 2020 VS 2026
- 2.3 Analysis of Competitive Landscape
- 2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
- 2.3.2 Global RNA Interference (RNAi) Drug Delivery Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 2.3.3 Global RNA Interference (RNAi) Drug Delivery Manufacturers Geographical Distribution
- 2.4 Key Trends for RNA Interference (RNAi) Drug Delivery Markets & Products
- 2.5 Primary Interviews with Key RNA Interference (RNAi) Drug Delivery Players (Opinion Leaders)
3 Market Size by Manufacturers
- 3.1 Global Top RNA Interference (RNAi) Drug Delivery Manufacturers by Production Capacity
- 3.1.1 Global Top RNA Interference (RNAi) Drug Delivery Manufacturers by Production Capacity (2015-2020)
- 3.1.2 Global Top RNA Interference (RNAi) Drug Delivery Manufacturers by Production (2015-2020)
- 3.1.3 Global Top RNA Interference (RNAi) Drug Delivery Manufacturers Market Share by Production
- 3.2 Global Top RNA Interference (RNAi) Drug Delivery Manufacturers by Revenue
- 3.2.1 Global Top RNA Interference (RNAi) Drug Delivery Manufacturers by Revenue (2015-2020)
- 3.2.2 Global Top RNA Interference (RNAi) Drug Delivery Manufacturers Market Share by Revenue (2015-2020)
- 3.2.3 Global Top 10 and Top 5 Companies by RNA Interference (RNAi) Drug Delivery Revenue in 2019
- 3.3 Global RNA Interference (RNAi) Drug Delivery Price by Manufacturers
- 3.4 Mergers & Acquisitions, Expansion Plans
4 RNA Interference (RNAi) Drug Delivery Production by Regions
- 4.1 Global RNA Interference (RNAi) Drug Delivery Historic Market Facts & Figures by Regions
- 4.1.1 Global Top RNA Interference (RNAi) Drug Delivery Regions by Production (2015-2020)
- 4.1.2 Global Top RNA Interference (RNAi) Drug Delivery Regions by Revenue (2015-2020)
- 4.2 North America
- 4.2.1 North America RNA Interference (RNAi) Drug Delivery Production (2015-2020)
- 4.2.2 North America RNA Interference (RNAi) Drug Delivery Revenue (2015-2020)
- 4.2.3 Key Players in North America
- 4.2.4 North America RNA Interference (RNAi) Drug Delivery Import & Export (2015-2020)
- 4.3 Europe
- 4.3.1 Europe RNA Interference (RNAi) Drug Delivery Production (2015-2020)
- 4.3.2 Europe RNA Interference (RNAi) Drug Delivery Revenue (2015-2020)
- 4.3.3 Key Players in Europe
- 4.3.4 Europe RNA Interference (RNAi) Drug Delivery Import & Export (2015-2020)
- 4.4 China
- 4.4.1 China RNA Interference (RNAi) Drug Delivery Production (2015-2020)
- 4.4.2 China RNA Interference (RNAi) Drug Delivery Revenue (2015-2020)
- 4.4.3 Key Players in China
- 4.4.4 China RNA Interference (RNAi) Drug Delivery Import & Export (2015-2020)
- 4.5 Japan
- 4.5.1 Japan RNA Interference (RNAi) Drug Delivery Production (2015-2020)
- 4.5.2 Japan RNA Interference (RNAi) Drug Delivery Revenue (2015-2020)
- 4.5.3 Key Players in Japan
- 4.5.4 Japan RNA Interference (RNAi) Drug Delivery Import & Export (2015-2020)
5 RNA Interference (RNAi) Drug Delivery Consumption by Region
- 5.1 Global Top RNA Interference (RNAi) Drug Delivery Regions by Consumption
- 5.1.1 Global Top RNA Interference (RNAi) Drug Delivery Regions by Consumption (2015-2020)
- 5.1.2 Global Top RNA Interference (RNAi) Drug Delivery Regions Market Share by Consumption (2015-2020)
- 5.2 North America
- 5.2.1 North America RNA Interference (RNAi) Drug Delivery Consumption by Application
- 5.2.2 North America RNA Interference (RNAi) Drug Delivery Consumption by Countries
- 5.2.3 U.S.
- 5.2.4 Canada
- 5.3 Europe
- 5.3.1 Europe RNA Interference (RNAi) Drug Delivery Consumption by Application
- 5.3.2 Europe RNA Interference (RNAi) Drug Delivery Consumption by Countries
- 5.3.3 Germany
- 5.3.4 France
- 5.3.5 U.K.
- 5.3.6 Italy
- 5.3.7 Russia
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific RNA Interference (RNAi) Drug Delivery Consumption by Application
- 5.4.2 Asia Pacific RNA Interference (RNAi) Drug Delivery Consumption by Regions
- 5.4.3 China
- 5.4.4 Japan
- 5.4.5 South Korea
- 5.4.6 India
- 5.4.7 Australia
- 5.4.8 Taiwan
- 5.4.9 Indonesia
- 5.4.10 Thailand
- 5.4.11 Malaysia
- 5.4.12 Philippines
- 5.4.13 Vietnam
- 5.5 Central & South America
- 5.5.1 Central & South America RNA Interference (RNAi) Drug Delivery Consumption by Application
- 5.5.2 Central & South America RNA Interference (RNAi) Drug Delivery Consumption by Country
- 5.5.3 Mexico
- 5.5.3 Brazil
- 5.5.3 Argentina
- 5.6 Middle East and Africa
- 5.6.1 Middle East and Africa RNA Interference (RNAi) Drug Delivery Consumption by Application
- 5.6.2 Middle East and Africa RNA Interference (RNAi) Drug Delivery Consumption by Countries
- 5.6.3 Turkey
- 5.6.4 Saudi Arabia
- 5.6.5 U.A.E
6 Market Size by Type (2015-2026)
- 6.1 Global RNA Interference (RNAi) Drug Delivery Market Size by Type (2015-2020)
- 6.1.1 Global RNA Interference (RNAi) Drug Delivery Production by Type (2015-2020)
- 6.1.2 Global RNA Interference (RNAi) Drug Delivery Revenue by Type (2015-2020)
- 6.1.3 RNA Interference (RNAi) Drug Delivery Price by Type (2015-2020)
- 6.2 Global RNA Interference (RNAi) Drug Delivery Market Forecast by Type (2021-2026)
- 6.2.1 Global RNA Interference (RNAi) Drug Delivery Production Forecast by Type (2021-2026)
- 6.2.2 Global RNA Interference (RNAi) Drug Delivery Revenue Forecast by Type (2021-2026)
- 6.2.3 Global RNA Interference (RNAi) Drug Delivery Price Forecast by Type (2021-2026)
- 6.3 Global RNA Interference (RNAi) Drug Delivery Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
7 Market Size by Application (2015-2026)
- 7.2.1 Global RNA Interference (RNAi) Drug Delivery Consumption Historic Breakdown by Application (2015-2020)
- 7.2.2 Global RNA Interference (RNAi) Drug Delivery Consumption Forecast by Application (2021-2026)
8 Corporate Profiles
- 8.1 Metabolic disorders
- 8.1.1 Metabolic disorders Corporation Information
- 8.1.2 Metabolic disorders Overview
- 8.1.3 Metabolic disorders Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
- 8.1.4 Metabolic disorders Product Description
- 8.1.5 Metabolic disorders Related Developments
- 8.2 Alnylam Pharmaceuticals Inc
- 8.2.1 Alnylam Pharmaceuticals Inc Corporation Information
- 8.2.2 Alnylam Pharmaceuticals Inc Overview
- 8.2.3 Alnylam Pharmaceuticals Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
- 8.2.4 Alnylam Pharmaceuticals Inc Product Description
- 8.2.5 Alnylam Pharmaceuticals Inc Related Developments
- 8.3 Merck & Co. Inc
- 8.3.1 Merck & Co. Inc Corporation Information
- 8.3.2 Merck & Co. Inc Overview
- 8.3.3 Merck & Co. Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
- 8.3.4 Merck & Co. Inc Product Description
- 8.3.5 Merck & Co. Inc Related Developments
- 8.4 Access Pharmaceuticals Inc
- 8.4.1 Access Pharmaceuticals Inc Corporation Information
- 8.4.2 Access Pharmaceuticals Inc Overview
- 8.4.3 Access Pharmaceuticals Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
- 8.4.4 Access Pharmaceuticals Inc Product Description
- 8.4.5 Access Pharmaceuticals Inc Related Developments
- 8.5 Dicerna Pharmaceuticals Inc
- 8.5.1 Dicerna Pharmaceuticals Inc Corporation Information
- 8.5.2 Dicerna Pharmaceuticals Inc Overview
- 8.5.3 Dicerna Pharmaceuticals Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
- 8.5.4 Dicerna Pharmaceuticals Inc Product Description
- 8.5.5 Dicerna Pharmaceuticals Inc Related Developments
- 8.6 Calondo Pharmaceuticals Inc
- 8.6.1 Calondo Pharmaceuticals Inc Corporation Information
- 8.6.2 Calondo Pharmaceuticals Inc Overview
- 8.6.3 Calondo Pharmaceuticals Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
- 8.6.4 Calondo Pharmaceuticals Inc Product Description
- 8.6.5 Calondo Pharmaceuticals Inc Related Developments
- 8.7 Marina Biotech Inc
- 8.7.1 Marina Biotech Inc Corporation Information
- 8.7.2 Marina Biotech Inc Overview
- 8.7.3 Marina Biotech Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
- 8.7.4 Marina Biotech Inc Product Description
- 8.7.5 Marina Biotech Inc Related Developments
- 8.8 RXi Pharmaceuticals Corp
- 8.8.1 RXi Pharmaceuticals Corp Corporation Information
- 8.8.2 RXi Pharmaceuticals Corp Overview
- 8.8.3 RXi Pharmaceuticals Corp Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
- 8.8.4 RXi Pharmaceuticals Corp Product Description
- 8.8.5 RXi Pharmaceuticals Corp Related Developments
- 8.9 Quark Pharmaceuticals Inc
- 8.9.1 Quark Pharmaceuticals Inc Corporation Information
- 8.9.2 Quark Pharmaceuticals Inc Overview
- 8.9.3 Quark Pharmaceuticals Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
- 8.9.4 Quark Pharmaceuticals Inc Product Description
- 8.9.5 Quark Pharmaceuticals Inc Related Developments
- 8.10 Silence Therapeutics plc
- 8.10.1 Silence Therapeutics plc Corporation Information
- 8.10.2 Silence Therapeutics plc Overview
- 8.10.3 Silence Therapeutics plc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
- 8.10.4 Silence Therapeutics plc Product Description
- 8.10.5 Silence Therapeutics plc Related Developments
- 8.11 Tacere Therapeutics Inc
- 8.11.1 Tacere Therapeutics Inc Corporation Information
- 8.11.2 Tacere Therapeutics Inc Overview
- 8.11.3 Tacere Therapeutics Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
- 8.11.4 Tacere Therapeutics Inc Product Description
- 8.11.5 Tacere Therapeutics Inc Related Developments
- 8.12 PhaseRx Inc
- 8.12.1 PhaseRx Inc Corporation Information
- 8.12.2 PhaseRx Inc Overview
- 8.12.3 PhaseRx Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
- 8.12.4 PhaseRx Inc Product Description
- 8.12.5 PhaseRx Inc Related Developments
- 8.13 Sirnaomics Inc
- 8.13.1 Sirnaomics Inc Corporation Information
- 8.13.2 Sirnaomics Inc Overview
- 8.13.3 Sirnaomics Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
- 8.13.4 Sirnaomics Inc Product Description
- 8.13.5 Sirnaomics Inc Related Developments
- 8.14 Traversa Therapeutics Inc
- 8.14.1 Traversa Therapeutics Inc Corporation Information
- 8.14.2 Traversa Therapeutics Inc Overview
- 8.14.3 Traversa Therapeutics Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)
- 8.14.4 Traversa Therapeutics Inc Product Description
- 8.14.5 Traversa Therapeutics Inc Related Developments
9 RNA Interference (RNAi) Drug Delivery Production Forecast by Regions
- 9.1 Global Top RNA Interference (RNAi) Drug Delivery Regions Forecast by Revenue (2021-2026)
- 9.2 Global Top RNA Interference (RNAi) Drug Delivery Regions Forecast by Production (2021-2026)
- 9.3 Key RNA Interference (RNAi) Drug Delivery Production Regions Forecast
- 9.3.1 North America
- 9.3.2 Europe
- 9.3.3 China
- 9.3.4 Japan
10 RNA Interference (RNAi) Drug Delivery Consumption Forecast by Region
- 10.1 Global RNA Interference (RNAi) Drug Delivery Consumption Forecast by Region (2021-2026)
- 10.2 North America RNA Interference (RNAi) Drug Delivery Consumption Forecast by Region (2021-2026)
- 10.3 Europe RNA Interference (RNAi) Drug Delivery Consumption Forecast by Region (2021-2026)
- 10.4 Asia Pacific RNA Interference (RNAi) Drug Delivery Consumption Forecast by Region (2021-2026)
- 10.5 Latin America RNA Interference (RNAi) Drug Delivery Consumption Forecast by Region (2021-2026)
- 10.6 Middle East and Africa RNA Interference (RNAi) Drug Delivery Consumption Forecast by Region (2021-2026)
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 RNA Interference (RNAi) Drug Delivery Sales Channels
- 11.2.2 RNA Interference (RNAi) Drug Delivery Distributors
- 11.3 RNA Interference (RNAi) Drug Delivery Customers
12 Market Opportunities & Challenges, Risks and Influences Factors Analysis
- 12.1 RNA Interference (RNAi) Drug Delivery Industry
- 12.2 Market Trends
- 12.3 Market Opportunities and Drivers
- 12.4 Market Challenges
- 12.5 RNA Interference (RNAi) Drug Delivery Market Risks/Restraints
- 12.6 Porter's Five Forces Analysis
13 Key Finding in The Global RNA Interference (RNAi) Drug Delivery Study
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.2 Data Source
- 14.2 Author Details
Summary:
Get latest Market Research Reports on RNA Interference (RNAi) Drug Delivery. Industry analysis & Market Report on RNA Interference (RNAi) Drug Delivery is a syndicated market report, published as Global RNA Interference (RNAi) Drug Delivery Market Insights and Forecast to 2026. It is complete Research Study and Industry Analysis of RNA Interference (RNAi) Drug Delivery market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
